Chengping Hu1, Donghai Yu2, Xirong Sun1, Ming Zhang3, Lin Wang1, Hongyun Qin3. 1. Pudong New District Mental Health Center,Shanghai,China. 2. Pudong New District Health Bureau,Shanghai,China. 3. Department of Psychiatric Control & Preventation,Pudong New District Mental Health Center,Shanghai,China.
Abstract
BACKGROUND: It has been reported that up to 42% of the population aged over 60 are affected by mild cognitive impairment (MCI) worldwide. This study aims to investigate the prevalence and progression of MCI through a meta-analysis. METHODS: We searched Embase and PubMed for relevant literature. Stable disease rate (SR), reversion rate (RR), dementia rate (DR), and Alzheimer's disease rate (AR) were used to evaluate the progression of MCI. The prevalence and progression rates were both obtained by reported percentile and indirect data analysis. Additionally, we carried out sensitivity analysis of each index by excluding some studies due to influence analysis with the most publication bias. RESULTS: Effect size (ES) was used to present adjusted overall prevalence (16%) and progression rates including SR (45%), RR (15%), DR (34%), and AR (28%) of MCI. Compared with clinic-based outcomes, MCI prevalence, SR, and RR are significantly higher in community, while DR and AR are lower. Despite significant heterogeneity found among the studies, no publication bias was observed. CONCLUSIONS: Age and gender were observed to be associated with MCI, in which age was considered as an impact factor for DR. The strong heterogeneity may result from variations in study design and baselines. Standardized MCI criteria were suggested to systematically evaluate MCI in the future.
BACKGROUND: It has been reported that up to 42% of the population aged over 60 are affected by mild cognitive impairment (MCI) worldwide. This study aims to investigate the prevalence and progression of MCI through a meta-analysis. METHODS: We searched Embase and PubMed for relevant literature. Stable disease rate (SR), reversion rate (RR), dementia rate (DR), and Alzheimer's disease rate (AR) were used to evaluate the progression of MCI. The prevalence and progression rates were both obtained by reported percentile and indirect data analysis. Additionally, we carried out sensitivity analysis of each index by excluding some studies due to influence analysis with the most publication bias. RESULTS: Effect size (ES) was used to present adjusted overall prevalence (16%) and progression rates including SR (45%), RR (15%), DR (34%), and AR (28%) of MCI. Compared with clinic-based outcomes, MCI prevalence, SR, and RR are significantly higher in community, while DR and AR are lower. Despite significant heterogeneity found among the studies, no publication bias was observed. CONCLUSIONS: Age and gender were observed to be associated with MCI, in which age was considered as an impact factor for DR. The strong heterogeneity may result from variations in study design and baselines. Standardized MCI criteria were suggested to systematically evaluate MCI in the future.
Authors: Julio Fernandez-Mendoza; Fan He; Kristina Puzino; Gregory Amatrudo; Susan Calhoun; Duanping Liao; Alexandros N Vgontzas; Edward Bixler Journal: Sleep Date: 2021-01-21 Impact factor: 5.849
Authors: Julio Fernandez-Mendoza; Fan He; Susan L Calhoun; Alexandros N Vgontzas; Duanping Liao; Edward O Bixler Journal: Sleep Health Date: 2019-11-21
Authors: Lilah M Besser; Lun-Ching Chang; Kelly R Evenson; Jana A Hirsch; Yvonne L Michael; James E Galvin; Stephen R Rapp; Annette L Fitzpatrick; Susan R Heckbert; Joel D Kaufman; Timothy M Hughes Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472